Dr. Niamh O'Boyle

• Greene TF, Wang S, Greene LM, Nathwani SM, Pollock JK, Malebari AM, McCabe T, Twamley B, O'Boyle NM, Zisterer DM, Meegan MJ, Synthesis and Biochemical Evaluation of 3-Phenoxy-1,4-diarylazetidin-2-ones as Tubulin-Targeting Antitumor Agents., Journal of Medicinal Chemistry, 59, (1), 2016, p90 - 113Journal Article, 2016, DOI , URL , TARA - Full Text
• Meegan MJ, Nathwani S, Twamley B, Zisterer DM, O'Boyle NM., Piperlongumine (piplartine) and analogues: Antiproliferative microtubule-destabilising agents., European Journal of Medicinal Chemistry, 125, 2017, p453 - 463Journal Article, 2017, DOI , TARA - Full Text
• O'Boyle NM, Pollock JK, Carr M, Knox AJ, Nathwani SM, Wang S, Caboni L, Zisterer DM, Meegan MJ., β-Lactam estrogen receptor antagonists and a dual-targeting estrogen receptor/tubulin ligand., Journal of medicinal chemistry, 57, (22), 2014, p9370-9382Journal Article, 2014, DOI
• Ann-Therese Karlberg, Kristina Luthman, Krister Holmberg, Niamh O'Boyle, Tamara Delaine, 'Resin compositions', Intellectual Property Office, GB1319110.1, 2013Patent, 2013, URL
• Daniela Zisterer, Mary Meegan, Niamh O'Boyle, Miriam Carr, Lisa Greene and Thomas Greene, 'Combretastatin Derivatives and Uses Therefor', European Patent Office, EP2338877 A1, 2009Patent, 2009, URL
• Malebari, AM, Greene, LM, Nathwani, SM, Fayne, D, O'Boyle, NM, Wang, S, Twamley, B, Zisterer, DM, Meegan, MJ, Beta-lactam analogues of combretastatin A-4 prevent metabolic inactivation by glucuronidation in chemoresistant HT-29 colon cancer cells, European Journal of Medicinal Chemistry, 130, 2017, p261-285Journal Article, 2017, DOI , URL
• O'Boyle, NM, Barrett, I, Greene, LM, Carr, M, Fayne, D, Twamley, B, Knox, AJS, Keely, NO, Zisterer, DM, Meegan, MJ, Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ER-alpha and ER-beta Activity, Journal of Medicinal Chemistry, 61, (2), 2018, p514 - 534Journal Article, 2018, DOI , URL , TARA - Full Text
• Hagvall, L, Niklasson, IB, Rudbäck, J, O'Boyle, NM, Niklasson, E, Luthman, K, Karlberg, A-T, Assessment of cross-reactivity of new less sensitizing epoxy resin monomers in epoxy resin-allergic individuals, Contact Dermatitis, 75, (3), 2016, p144-150Journal Article, 2016, DOI , URL
• Pollock JK, Greene LM, Nathwani SM, Kinsella P, O'Boyle NM, Meegan MJ, Zisterer DM., Involvement of NF-kB in mediating the anti-tumour effects of combretastatins in T cells., Investigational new drugs, 36, (4), 2018, p523-535Journal Article, 2018, DOI
• Wang, S., Malebari, A.M., Greene, T.F., O'Boyle, N.M., Fayne, D., Nathwani, S.M., Twamley, B., McCabe, T., Keely, N.O., Zisterer, D.M. and Meegan, M.J., 3-Vinylazetidin-2-Ones: Synthesis, antiproliferative and tubulin destabilizing activity in MCF-7 and MDA-MB-231 Breast Cancer Cells, Pharmaceuticals, 12, (2), 2019Journal Article, 2019, DOI
• Niamh M. O'Boyle, Gloria Ana, Patrick M. Kelly, Seema M. Nathwani, Sara Noorani, Darren Fayne, Sandra A. Bright, Brendan Twamley, Daniela M. Zisterer, Mary J. Meegan, Synthesis and evaluation of antiproliferative microtubule-destabilising combretastatin A-4 piperazine conjugates, Organic & Biomolecular Chemistry, 17, 2019, p6184 - 6200Journal Article, 2019, DOI , URL
• Mary J. Meegan and Niamh M. O'Boyle, Anticancer Drugs, 1, MDPI, 2019Book, 2019, URL
• Eavan C. McLoughlin and Niamh M. O'Boyle, Colchicine-Binding Site Inhibitors from Chemistry to Clinic: A Review , Pharmaceuticals, 13, (1), 2020Journal Article, 2020, DOI , URL
• Miriam Carr, Andrew J.S. Knox, Daniel K. Nevin, Niamh O'Boyle, Shu Wang, Billy Egan, Thomas McCabe, Brendan Twamley, Daniela M. Zisterer, David G. Lloyd, Mary J. Meegan, Optimisation of Estrogen Receptor Subtype-Selectivity of a 4-Aryl-4H-Chromene Scaffold Previously Identified by Virtual Screening, Bioorganic & Medicinal Chemistry, 28, (5), 2020, p115261-Journal Article, 2020
• Twamley, B., O'Boyle, N.M., Meegan, M.J., Azetidin-2-ones: Structures of antimitotic compounds based on the 1-(3,4,5-trimethoxyphenyl)azetidin-2-one core, Acta Crystallographica Section E: Crystallographic Communications, 76, 2020, p1187 - 1194Journal Article, 2020, DOI , URL
• T. S. Ibrahim, M. M. Hawwas, A. M. Malebari, E. S. Taher, A. M. Omar, N. M. O'Boyle, E. McLoughlin, Z.K. Abdel-Samii, Y. A. M. M. Elshaier, Potent Quinoline-Containing Combretastatin A-4 Analogues: Design, Synthesis, Antiproliferative, and Anti-Tubulin Activity, Pharmaceuticals, 13, (11), 2020, p393-Journal Article, 2020, DOI , URL
• Sophie Knox, Niamh M. O'Boyle, Skin Lipids in Health and Disease: A Review, Chemistry and Physics of Lipids, 236, 2021, p105055Journal Article, 2021, DOI , URL
• Gloria Ana, Patrick M. Kelly, Azizah M. Malebari, Sara Noorani, Seema M. Nathwani, Brendan Twamley, Darren Fayne, Niamh M. O'Boyle, Daniela M. Zisterer, Elisangela Flavia Pimentel, Denise Coutinho Endringer and Mary J. Meegan, Synthesis and Biological Evaluation of 1-(Diarylmethyl)-1H-1,2,4-Triazoles and 1-(Diarylmethyl)-1H-Imidazoles as a Novel Class of Anti-Mitotic Agent for Activity in Breast Cancer, Pharmaceuticals, 14, (2), 2021, p169-Journal Article, 2021, DOI , URL
• Malebari A.M., Wang S., Greene T.F., O'Boyle N.M., Fayne D., Khan M.F., Nathwani S.M., Twamley B., McCabe T., Zisterer D.M., Meegan M.J., Synthesis and antiproliferative evaluation of 3-chloroazetidin-2-ones with antimitotic activity: Heterocyclic bridged analogues of combretastatin A-4, Pharmaceuticals, 14, (11), 2021, part. 1119-Journal Article, 2021, DOI
• O'Boyle, Niamh; Niklasson, Ida; Ponting, David; Ortega, Miguel; Seifert, Tina; Natsch, Andreas; Luthman, Kristina; Karlberg, Ann-Therese, Nature-Derived Epoxy Resins: Synthesis, Allergenicity and Thermosetting Properties of Pinoresinol Diglycidyl Ether, Toxicology and Industrial Health, 38, (5), 2022, p259-269Journal Article, 2022
• Mary J. Meegan and Niamh M. O'Boyle, Anticancer Drugs 2021, MDPI, 2021Book, 2021, URL
• McLoughlin, E.C. and O'Boyle, N.M., Correction: Colchicine-binding site inhibitors from chemistry to clinic: A review. (Pharmaceuticals, (2020)13, 8), Pharmaceuticals, 13, (4), 2020Journal Article, 2020, DOI , URL
• Malebari, A.M. and Fayne, D. and Nathwani, S.M. and O'Connell, F. and Noorani, S. and Twamley, B. and O'Boyle, N.M. and O'Sullivan, J. and Zisterer, D.M. and Meegan, M.J., Beta-Lactams with antiproliferative and antiapoptotic activity in breast and chemoresistant colon cancer cells, European Journal of Medicinal Chemistry, 189, (112050), 2020Journal Article, 2020, DOI , URL
• Malebari, A.M. and Greene, L.M. and Nathwani, S.M. and Fayne, D. and O'Boyle, N.M. and Wang, S. and Twamley, B. and Zisterer, D.M. and Meegan, M.J., β-Lactam analogues of combretastatin A-4 prevent metabolic inactivation by glucuronidation in chemoresistant HT-29 colon cancer cells, European Journal of Medicinal Chemistry, 130, 2017, p261-285Journal Article, 2017, DOI , URL
• McLoughlin EC, O'Brien JE, Trujillo C, Meegan MJ, O'Boyle NM., Application of 2D EXSY and qNMR Spectroscopy for Diastereomeric Excess Determination Following Chiral Resolution of Beta-Lactams, ChemistryOpen, 2022, pe202200119Journal Article, 2022, DOI
• Knox S, Hagvall L, Malmberg P, O'Boyle NM., Topical Application of Metal Allergens Induces Changes to Lipid Composition of Human Skin., Frontiers in Toxicology, 4, 2022, p867163Journal Article, 2022, DOI , URL
• Malebari AM, Duffy Morales G, Twamley B, Fayne D, Khan MF, McLoughlin EC, O'Boyle NM, Zisterer DM, Meegan MJ., Synthesis, Characterisation and Mechanism of Action of Anticancer 3-Fluoroazetidin-2-ones., Pharmaceuticals (Basel, Switzerland), 15, (9), 2022, p1044Journal Article, 2022, DOI
• Malebari, A.M. and Fayne, D. and Nathwani, S.M. and O'Connell, F. and Noorani, S. and Twamley, B. and O'Boyle, N.M. and O'Sullivan, J. and Zisterer, D.M. and Meegan, M.J., β-Lactams with antiproliferative and antiapoptotic activity in breast and chemoresistant colon cancer cells, European Journal of Medicinal Chemistry, 189, (112050), 2020Journal Article, 2020, DOI , URL
• Wang S., Malebari A.M., Greene T.F., Kandwal S., Fayne D., Nathwani S.M., Zisterer D.M., Twamley B., O'Boyle N.M., Meegan M.J., Antiproliferative and Tubulin-Destabilising Effects of 3-(Prop-1-en-2-yl)azetidin-2-Ones and Related Compounds in MCF-7 and MDA-MB-231 Breast Cancer Cells, Pharmaceuticals, 16, (7), 2023, p1000-Journal Article, 2023, DOI , URL
• McLoughlin E.C., Twamley B., O'Brien J.E., Hannon Barroeta P., Zisterer D.M., Meegan M.J., O'Boyle N.M., Synthesis by diastereomeric resolution, biochemical evaluation and molecular modelling of chiral 3-hydroxyl b-lactam microtubule-targeting agents for the treatment of triple negative breast and chemoresistant colorectal cancers, Bioorganic Chemistry, 141, 2023Journal Article, 2023, DOI , URL
• Byrne A.J., Bright S.A., McKeown J.P., Bergin A., Twamley B., McElligott A.M., Noorani S., Kandwal S., Fayne D., O'Boyle N.M., Williams D.C., Meegan M.J., Synthesis and Pro-Apoptotic Effects of Nitrovinylanthracenes and Related Compounds in Chronic Lymphocytic Leukaemia (CLL) and Burkitt's Lymphoma (BL), Molecules, 28, (24), 2023Journal Article, 2023, DOI
• McVicker RU, O'Boyle NM., Chirality of New Drug Approvals (2013-2022): Trends and Perspectives., Journal of Medicinal Chemistry, 67, (4), 2024, p2305-2320Journal Article, 2024, DOI , URL
• James Patrick McKeown, Andrew J Byrne, Sandra A Bright, Clara E Charleton, Shubhangi Kandwal, Ivan Cmelo, Brendan Twamley, Anthony M McElligott, Darren Fayne, Niamh M O'Boyle, D.Clive Williams, Mary Jane Meegan, Synthesis and Biochemical evaluation of Ethanoanthracenes and Related Compounds: Antiproliferative and Pro-apoptotic Effects in Chronic Lymphocytic Leukaemia (CLL), Pharmaceuticals, 17, (8), 2024, p1034Journal Article, 2024, DOI , URL
• McLoughlin EC, Twamley B, O'Boyle NM., Candida antarctica Lipase B mediated kinetic resolution: A sustainable method for chiral synthesis of antiproliferative ß-lactams., European Journal of Medicinal Chemistry, 276, 2024, p116692Journal Article, 2024, DOI , URL
• Moore AI, Moreira ASP, Guerra IMS, Goracci L, Domingues P, Melo T, Domingues MR, O'Boyle NM., A lipidomic approach towards identifying the effects of fragrance hydroperoxides on keratinocytes., Contact dermatitis, 92, (3), 2025, p176 - 186Journal Article, 2025, DOI , URL
• Ana G, Malebari AM, Noorani S, Fayne D, O'Boyle NM, Zisterer DM, Pimentel EF, Endringer DC, Meegan MJ., (E)-1-(3-(3-Hydroxy-4-Methoxyphenyl)-1-(3,4,5-Trimethoxyphenyl)allyl)-1H-1,2,4-Triazole and Related Compounds: Their Synthesis and Biological Evaluation as Novel Antimitotic Agents Targeting Breast Cancer., Pharmaceuticals (Basel, Switzerland), 18, (1), 2025, p118Journal Article, 2025
• Bayraktar G, Carro L, Decker M, Giuntini F, Helesbeux JJ, Marchand P, Matthews SE, McCarthy FO, Mistry SN, Moreira VM, O'Boyle NM, Pace V, Rochais C, Saylam M, Sotelo E., Shaping Future Medicinal Chemists: Perspectives from European Schools of Pharmacy within the GP2A Network., Journal of medicinal chemistry, 2025Journal Article, 2025, DOI , URL
• Ndreu L., Carlsson J., Ponting D.J., Niklasson I.B., Steen E.J.L., McHugh L., O'Boyle N.M., Luthman K., Karlberg A.-T., Karlsson I., Bioactivation of cinnamic alcohol in a reconstructed human epidermis model and evaluation of sensitizing potency of the identified metabolites, Frontiers in Toxicology, 6, 2024Journal Article, 2024, DOI , URL
• Moore, Aaron I., Moreira, Ana S. P., Conde, Tiago, Melo, Tania, Domingues, Pedro, O'Boyle, Niamh M., Domingues, M. Rosario, Terpene Hydroperoxides as Lipid Peroxidation Inducers: Biomimetic and HaCaT Cell Studies in Allergic Contact Dermatitis, Contact Dermatitis, 93, (1), 2025, p16-30Journal Article, 2025, DOI , URL
• Tonelotto, Valentina, Qaisar, Alina, McLoughlin, Eavan C., Cassaday, Amelia, Kundu, Karishma, Pendino, Marzia, Marcone, Simone, O'Sullivan, Jacintha, Twamley, Brendan, Jensen, Lasse D., Thorpe, Stephen D., Kennedy, Breandán N. and O'Boyle, Niamh M., Characterization of a water soluble quininib prodrug that blocks metabolic activity and proliferation of multiple cancer cell lines, European Journal of Medicinal Chemistry, 296, 2025Journal Article, 2025, DOI , URL
• Matthew Ward, Niamh M. O'Boyle, Analysis of the structural diversity of heterocycles amongst European medicines agency approved pharmaceuticals (2014-2023), RSC Medicinal Chemistry, 16, (10), 2025, p4540-4570Journal Article, 2025
• Fiona Sexton, Julia O'Mahony, Sumera Sumera, Romina Golchin, Anne Lonergan, Siobhan McCarthy, Cecilia Svedman, Martin Mowitz, Niamh O'Boyle, Colin P Hawkes, John Bourke, Culprit allergens in diabetes technology-associated allergic contact dermatitis: investigation remains challenging, British Journal of Dermatology, 193, (4), 2025, p792-794Journal Article, 2025, DOI , URL
• Sofia Botvid, Helen Vaher, Alexandra T. Seibel, Aaron Moore, Niamh O'Boyle, Lina Hagvall, Niels Højsager Bennike, Charlotte Menné Bonefeld, Jeanne Duus Johansen, FS-10 Repeated open application test (ROAT) with hydroperoxides of linalool, Contact Dermatitis, 16th Congress of the European Society of Contact Dermatitis (ESCD), Dresden, Germany, September 2024, 91, (S1), 2024Published Abstract, 2024, DOI , URL
• Aoife Clancy, Lina Hagvall, Per Malmberg, Niamh O'Boyle, FS-12 Skin deep: The distribution and effects of methylisothiazolinone and fragrances in the skin, Contact Dermatitis, 16th Congress of the European Society of Contact Dermatitis (ESCD), Dresden, Germany, September 2024, 91, (S1), 2024Oral Presentation, 2024, DOI , URL
• Aoife Clancy, Lina Hagvall, Per Malmberg, Niamh O'Boyle, P-18 Using ToF-SIMS to investigate skin lipid composition upon exposure to allergens, Contact Dermatitis, 16th Congress of the European Society of Contact Dermatitis (ESCD), Dresden, Germany, September 2024, 91, (S1), 2024Poster, 2024, DOI , URL
• O'Boyle, NM, Greene, LM, Bergin, O, Fichet, JB, McCabe, T, Lloyd, DG, Zisterer, DM, Meegan, MJ, Synthesis, evaluation and structural studies of antiproliferative tubulin-targeting azetidin-2-ones, Bioorganic & Medicinal Chemistry, 19, (7), 2011, p2306-2325Journal Article, 2011, DOI , URL , TARA - Full Text
• O'Boyle, NM, Carr, M, Greene, LM, Keely, NO, Knox, AJS, McCabe, T, Lloyd, DG, Zisterer, DM, Meegan, MJ, Synthesis, Biochemical and Molecular Modelling Studies of Antiproliferative Azetidinones causing Microtubule Disruption and Mitotic Catastrophe, European Journal of Medicinal Chemistry, 46, (9), 2011, p4595 - 4607Journal Article, 2011, DOI , URL , TARA - Full Text
• O'Boyle, N.M., Knox, A.J.S., Price, T.P., Williams, D.C., Zisterer, D.M., Lloyd, D.G., Meegan, M.J., Lead identification of beta-lactam and related imine inhibitors of the molecular chaperone heat shock protein 90, Bioorganic & Medicinal Chemistry, 19, (20), 2011, p6055-6068Journal Article, 2011, DOI , URL , TARA - Full Text
• O'Boyle NM, Carr M, Greene LM, Bergin O, Nathwani SM, McCabe T, Lloyd DG, Zisterer DM, Meegan MJ, Synthesis and evaluation of azetidinone analogues of combretastatin A-4 as tubulin targeting agents, Journal of Medicinal Chemistry, 53, (24), 2010, p8569-8584Journal Article, 2010, DOI , URL , TARA - Full Text
• O'Boyle, NM, Greene, LM, Keely, NO, Wang, S, Cotter, TS, Zisterer, DM, Meegan, MJ, Synthesis and biochemical activities of antiproliferative amino acid and phosphate derivatives of microtubule-disrupting beta-lactam combretastatins, EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 62, 2013, p705-721Journal Article, 2013, DOI
• Nathwani, S. M., Hughes, L., Greene, L. M., Carr, M., O'Boyle, N. M., McDonnell, S., Meegan, M. J., Zisterer, D. M., Novel cis-restricted beta-lactam combretastatin A-4 analogues display anti-vascular and anti-metastatic properties in vitro,, Oncol Rep, 29, (2), 2013, p585 - 594Journal Article, 2013
• O'Boyle, NM, Pollock, JK, Carr, M, Knox, AJS, Nathwani, SM, Wang, S, Caboni, L, Zisterer, DM, Meegan, MJ, Beta-Lactam Estrogen Receptor Antagonists and a Dual-Targeting Estrogen Receptor/Tubulin Ligand, Journal of Medicinal Chemistry, 57, (22), 2014, p9370 - 9382Journal Article, 2014, DOI , URL , TARA - Full Text
• O'Boyle, NM, Niklasson, IB, Tehrani-Bagha,AR, Delaine, T, Holmberg, K, Luthman, K, Karlberg, AT, Epoxy resin monomers with reduced skin sensitizing potency, Chemical Research in Toxicology, 27, (6), 2014, p1002-1010Journal Article, 2014, DOI , TARA - Full Text
• Pollock, JK, Verma,NK, O'Boyle, NM, Carr, MG, Meegan, MJ, Zisterer, DM, Combretastatin (CA)-4 and its novel analogue CA-432 impair T-cell migration through the Rho/ROCK signalling pathway, Biochemical Pharmacology, 92, (4), 2014, p544-557Journal Article, 2014, DOI
• Greene, LM, Wang, S, O'Boyle, NM, Bright, SA, Reid, JEA, Kelly, PJ, Meegan, MJ, Zisterer, DM, Combretazet-3 a novel synthetic cis-stable combretastatin A-4-azetidinone hybrid with enhanced stability and therapeutic efficacy in colon cancer, Oncology Reports, 29, (6), 2013, p2451-2458Journal Article, 2013, DOI
• O'Boyle, NM, Delaine, T, Luthman, K, Natsch, A, Karlberg, AT, Analogues of the epoxy resin monomer diglycidyl ether of bisphenol F: Effects on contact allergenic potency and cytotoxicity, Chemical Research in Toxicology, 25, (11), 2012, p2469-2478Journal Article, 2012, DOI , TARA - Full Text
• Greene, LM, O'Boyle, NM, Nolan, DP, Meegan, MJ, Zisterer, DM, The vascular targeting agent Combretastatin-A4 directly induces autophagy in adenocarcinoma-derived colon cancer cells, Biochemical Pharmacology, 84, (5), 2012, p612-624Journal Article, 2012, DOI
• O'Boyle, NM, Meegan, MJ, Designed multiple ligands for cancer therapy, Current Medicinal Chemistry, 18, (31), 2011, p4722-4737Journal Article, 2011, DOI
• Yang,Y., Carta,G., Peters, M.B., Price, T.T., O'Boyle, N.M., Knox, A.J.S., Fayne, D., Williams, D.C., Meegan, M.J., Lloyd, D.G., 'TieredScreen' - Layered virtual screening tool for the identification of novel estrogen receptor alpha modulators, Molecular Informatics, 29, (5), 2010, p421-430Journal Article, 2010, DOI
• Barrett, I., Carr, M.G., O'Boyle, N.M., Greene, L.M., Knox, A., Lloyd, D.G., Zisterer, D.M., Meegan, M.J., Lead identification of conformationally restricted benzoxepin type combretastatin analogs: Synthesis, antiproliferative activity, and tubulin effects, Journal of Enzyme Inhibition and Medicinal Chemistry, 25, (2), 2010, p180-194Journal Article, 2010, DOI
• Greene,. L.M., Nathwani, S.M., Bright, S.A., Fayne, D., Croke, A., Gagliardi,M., McElligott, A.M., O'Connor, L.M., Carr, M.G., Keely, N.O., O'Boyle, N.M., Carroll, P.V., Sarkadi, B., Conneally, E.C., Lloyd,D.G., Lawler, M.P., Meegan, M.J., Zisterer, D.M., The vascular targeting agent combretastatin-A4 and a novel cis-restricted beta-lactam analogue, CA-432, induce apoptosis in human chronic myeloid leukemia cells and ex vivo patient samples including those displaying multidrug resistance, Journal of Pharmacology and Experimental Therapeutics, 335, (2), 2010, p302-313Journal Article, 2010, DOI

• Niamh M. O'Boyle, Daniela M. Zisterer, Mary J. Meegan, Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERalpha and ERbeta Activity, Proceedings of the 3rd Int. Electron. Conf. Med. Chem., 3rd International Electronic Conference on Medicinal Chemistry, November 2017, edited by Annie Mayence and Jean Jacques Vanden Eynde , 11, (1), Pharmaceuticals, 2017, pp18-Conference Paper, DOI , URL
• Niamh M. O'Boyle, Daniela M. Zisterer, Mary J. Meegan, Microtubule-Destabilising Actions of Piperlongumine and Analogues, Proceedings of the 3rd Int. Electron. Conf. Med. Chem., 3rd International Electronic Conference on Medicinal Chemistry, November 2017, edited by Annie Mayence and Jean Jacques Vanden Eynde , 11, (1), Pharmaceuticals, 2017, pp18-Conference Paper, DOI , URL
• James Patrick Mc Keown, Clara Charleton, Keith Ferris, Sara Noorani, Niamh M O'Boyle, Mary J Meegan, Ethanoanthracenes: Potential chemotherapeutics for chronic lymphocytic leukaemia (CLL), 4th International Electronic Conference on Medicinal Chemistry, Online at www.sciforum.net/conference/ecmc-4, November 2018, edited by MDPI , 2018Poster, DOI , URL
• Eavan Ciara McLoughlin, Mary Meegan, Niamh O'Boyle, Stories from Staudinger: Synthesis of chiral beta-lactams, 5th International Electronic Conference on Medicinal Chemistry, Online at https://sciforum.net/conference/ECMC2019, November 2019, 2019Poster, DOI , URL
• Niamh O'Boyle, Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERalpha and ERbeta Activity, 26th Annual GP2A Medicinal Chemistry Conference & 32nd Journées Franco-Belges de Pharmacochimie, Asnelles sur Mer, Normandie, France, 13th June 2018, 2018, GP2AInvited Talk, DOI , URL , TARA - Full Text
• Niamh O'Boyle, Epoxy Resins: From Chemistry to Clinic, Occupational and Environmental Exposure of the Skin to Chemicals, Dublin, 16 - 18 Sept. 2019, 2019Oral Presentation, URL , TARA - Full Text
• Niamh O'Boyle, Organic chemistry practicals: introduction of pre-laboratory assessments for first year pharmacy students, Irish Variety in Chemistry Education 2019, Dublin Institute of Technology, Kevin Street, 26th April 2019, edited by Claire McDonnell , 2019Oral Presentation, URL
• Niamh O'Boyle, Designing a capacity plan for the Aseptic Compounding Unit in St. James's Hospital, Irish Pharmacy Journal , 85, 2007, p303 - 306Journal Article, URL
• Eavan C. McLoughlin, Niamh M. O'Boyle, Combretazets: Enantiomeric Beta-Lactams for the Treatment of Breast Cancer, 6th International Electronic Conference on Medicinal Chemistry, 01-30 November 2020, edited by Dr. Jean Jacques Vanden Eynde , MDPI, 2020Oral Presentation, DOI , URL
• Niamh O'Boyle, Probing the Skin with ToF-SIMS: do Metal Allergens Change Lipid Composition?, 29th Meeting of the European Research Group on Experimental Contact Dermatitis, Online, 3rd February, 2021Invited Talk
• Helesbeux J.-J., Carro L., McCarthy F.O., Moreira V.M., Giuntini F., O'Boyle N.M., Matthews S.E., Bayraktar G., Bertrand S., Rochais C., Marchand P., 29th Annual GP2A Medicinal Chemistry Conference, Pharmaceuticals, 14, (12), 2021, part. 1278Journal Article, DOI
• Eavan C. McLoughlin, Nithya Valupadasu, Niamh M. O'Boyle, A phosphate prodrug of pyrazinib: Improved solubility and antiproliferative activity, 7th International Electronic Conference on Medicinal Chemistry, November 2021, edited by Jean Jacques Vanden Eynde , 2021Poster, DOI , URL
• Mary J. Meegan and Niamh M. O'Boyle, Special Issue 'Anticancer Drugs 2021', Pharmaceuticals, 15, (4), 2022, p479-Journal Article, DOI , URL
• Niamh M. O'Boyle, Targeting Tubulin - a Tale of the Development of the Combretazets, SCF 29th Young Research Fellows Meeting, Nantes, 4-6 July 2022, 2022, Société de Chimie ThérapeutiqueInvited Talk, URL , TARA - Full Text
• Niamh M. O'Boyle, FS-44: Nature-Inspired Epoxy Resins: PinoDGE, Contact Dermatitis, European Society for Contact Dermatitis 15th Congress, Amsterdam, 8-10 June 2022, 86, (S1), Wiley, 2022, pp20-Oral Presentation, URL , TARA - Full Text
• Niamh M. O'Boyle, FC-48: Probing the skin with ToF-SIMS: skin lipid composition upon exposure to metal allergens, Contact Dermatitis, European Society for Contact Dermatitis 15th Congress, Amsterdam, 8-10 July 2022, 86, (S1), Wiley, 2022, pp54 - 55Oral Presentation, DOI , URL , TARA - Full Text
• Alina Qaisar, Jacintha O'Sullivan, Niamh M. O'Boyle, P22: Synthesis and Physicochemical Properties of Amino Acid Prodrugs of the Radiosensitser Pyrazinib, 30th Annual GP2A Medicinal Chemistry Conference, Dublin, 24-26 August 2022, 2022Poster
• Eavan C. McLoughlin, Patricia Hannon Barroeta, Daniela M. Zisterer, and Niamh M. O'Boyle, P41: A comparison of chiral diastereomeric versus kinetic enzymatic resolution for enantioseparation of microtubule depolymerising beta-lactams, 30th Annual GP2A Medicinal Chemistry Conference, Dublin, 24-26 August 2022, 2022Poster
• Niamh O'Boyle(ed.), 30th Annual GP2A Medicinal Chemistry Conference, Pharmaceuticals, Trinity College Dublin, Ireland, 16, (3), 24-26th August 2022, 2023, 432-Proceedings of a Conference, DOI , URL
• Eavan C. McLoughlin , Niamh M. O'Boyle, A biocatalytic approach for kinetic resolution toward enantiopure anti-cancer beta-lactams using Candida antarctica Lipase B, 9th International Electronic Conference on Medicinal Chemistry, 1-30 November 2023, edited by Alfredo Berzal-Herranz , 2023Poster, DOI , URL
• Breandan N Kennedy; Eavan McLoughlin; Alina Qaisar; Amelia Cassaday; Marzia Pendino; Simeone Marcone; Jacintha O'Sullivan; Niamh O'Boyle; Valentina Tonelotto, A Water Soluble Quininib Analogue Blocks Metabolic Activity and Proliferation of OMM2.5 Metastatic Uveal Melanoma Cells, Investigative Ophthalmology & Visual Science, ARVO Annual Meeting, Seattle, USA, 2024, 65, 2024, pp2258-Poster, URL
• Fiona Sexton, Julia O'Mahony, Sumera Sumera, Romina Golchin, Cecilia Svedman, Niamh O'Boyle, Colin P Hawkes, John Bourke, CD02 Colophonium derivatives as key allergens in diabetes technology-associated allergic contact dermatitis: a hidden concern in the British Society for Cutaneous Allergy standard series, British Journal of Dermatology, 105th Annual Meeting of the British Association of Dermatologists, Glasgow, Scotland, 193, (Supplement 1), 2025Published Abstract, DOI , URL
• Ellie Swords, Eve O'Reilly, Niamh Stephens, Alina Qaisar, Silvia Illa-Tuset, Rob Scoffin, Colm J. Ryan, Niamh O'Boyle, Valentina Tonelotto, Breandán N. Kennedy, Investigating the Therapeutic Potential of Drug Combinations in Pre-Clinical Models of Metastatic Uveal Melanoma, UCD Conway Festival of Research, University College Dublin, October 2024, 2024Poster
• Aoife Clancy, Anne-Marie Tobin, Fei Lei, Derek G. Doherty, Niamh M. O'Boyle, Investigating the Role of CD1a and CD1d in Nickel Allergic Contact Dermatitis, CD1-MR1 2025 Conference, Portland, OR, USA, 2025, 2025Poster
• Aaron I. Moore, Ana S. P. Moreira, Tiago Conde, Pedro Domingues, Tânia Melo, Niamh M. O'Boyle, M. Rosário Domingues, Exploring the Potential of Terpene Hydroperoxides to Induce Lipid Peroxidation and Their Role in Contact Allergy, Lipids in Cellular Function and Disease, Beaver Run Conference Center, Breckenridge, CO, United States, April 2025, 2025Poster
• JL Wong, N O'Boyle, L O'Driscoll, 343 Extracellular Vesicles Released from Skin Keratinocytes in Response to Contact Allergens, Journal of Investigative Dermatology, ESDR 2025, Antwerp, Belgium, September 2025, 145, (12), 2025, ppS326-Published Abstract, DOI , URL

Dr. O'Boyle leads a research group that is at the forefront of two fields: developing treatments for drug-resistant cancers and discovering mechanisms of skin allergy. Both are concerned with the intricate interactions between chemicals and the human body. In the inflammation strand of her research, she is elucidating the reasons that certain chemicals cause skin allergy. This had led to a new research area: the characterisation of the effects of chemicals on skin lipids. The key direction of this research is improving the understanding of the molecular mechanisms of skin allergy, leading to improved diagnostics and treatments. In the cancer strand of her research, she is focused on developing treatments for multi-drug resistant cancers and uveal melanoma. Dr. O'Boyle consistently publishes in international peer-reviewed articles, and has also co-edited two books and is a co-inventor on two patents. She has been a keynote speaker at many conferences and seminars. Her research has been supported by the Irish Research Council, CAMS-UK, Wellcome Trust, Enterprise Ireland, Royal Society of Chemistry, H2020-MSCA-RISE (CRYSTAL3 and EVEREST), Panoz Pharmaceutical Innovation PhD scholarships), Trinity College (Trinity Research Boost, Provost's PhD Project Award and Dean of Health Sciences Award), Research Ireland, Horizon-Europe Marie Sklodowska-Curie Doctoral-Network (eRaDicate), Breakthrough Cancer Research and the City of Dublin Skin and Cancer Hospital Charity.

• Title

  Analysis of Skin Lipids in Contact Allergy by Mass Spectrometry
  Summary
  Funding Agency

  CAMS-UK and Royal Society of Chemistry
  Date From

  August 2020
  Date To

  September 2021
• Title

  Biochemical Evaluation of the 'Combretazets' - Novel and Potent Drugs for Treating Multi-Drug Resistant Cancers
  Summary

  The aim of this project is to evaluate the biochemical effects of novel, enantiomerally pure β-lactams on breast cancer cells. Specific assays will investigate effects on breast cancer cell proliferation, cell cycle, apoptosis and tubulin polymerisation. This will enable us to identify the best drug candidate for progression to pre-clinical experiments, e.g. in vivo assessment.
  Funding Agency

  Wellcome Trust Institutional Strategic Support Fund
• Title

  Assessment of Skin Allergens in Diabetic Glucose Sensors and Insulin Pumps
  Summary

  Continuous glucose-monitoring devices and insulin pump systems have become an essential component of the management of diabetes, a chronic disease that affects over 500 million people worldwide. As the prevalence of diabetes increases, the use of these devices is also expanding. These devices are affixed to the patient"s skin using an adhesive patch. Allergic contact dermatitis (ACD) to components of glucose-monitoring sensors and insulin pumps is increasingly problematic as disease management becomes dependent on wearable technologies. To date, the most common identified skin allergens fall into two broad classes: acrylates and colophonium-related substances. However, the range of skin allergens discovered in both the devices and the adhesive patches is constantly expanding. Although patch testing is useful in identifying potential allergens, many studies to date have not analysed the chemical composition of the devices. The objective of this project is to analyse diabetic medical devices to understand what allergenic chemicals are present, focusing on emerging skin allergens.
  Funding Agency

  City of Dublin Skin and Cancer Hospital Charity
• Title

  Synthesis of Novel Cysteinyl Leukotriene Receptor 1 Antagonists for the Treatment of Uveal Melanoma: Optimisation of Identified Hits into Potential Drug Candidates
  Summary

  Uveal melanoma (UM) is an eye cancer. In half of UM patients, the cancer spreads to the liver. There are no good treatments for preventing the cancer from spreading or for treating the cancer once it has spread. Therefore, there is a clear need to develop new medicines for this disease. Cysteinyl leukotriene receptor 1 (CysLTR1) is a protein present naturally in humans. Studies have shown high levels of CysLTR1 in many cancers, and links between CysLTR1 and poor outcomes. Some studies have shown that medicines that block the action of CysLTR1 decrease cancer risk. Therefore, CysLTR1 antagonists could be a useful new UM treatment option. Two exciting new CysLTR1 antagonist drugs have been discovered " quininib and `M6". Quininib has been shown to prevent blood vessel formation (a way that cancer spreads) in zebrafish eyes, and a very similar drug (1,4-dihydroxy quininib) has been shown to kill UM cells and cause other changes in their behaviour. M6, a more recently discovered and less-studied drug, can block CysLTR1, is non-toxic to zebrafish and prevents zebrafish blood vessel formation. This is promising, but neither quininib nor M6 is `patient-ready". There are opportunities for strengthening drug action so that lower doses are needed for treatment. This research will involve synthesising new drugs similar to M6 and quininib but with strategic chemistry changes, to try to give the drugs better activity against UM. These drugs will then be tested using UM cells and zebrafish, ultimately to develop a drug that could one day be used to treat UM patients.
  Funding Agency

  Research Ireland & Breakthrough Cancer Research
• Title

  Development of Novel Anti-Tumour Beta-Lactams for Treatment of Aggressive Breast Cancer
  Summary

  Triple-negative breast cancer (TNBC) is the most aggressive and lethal form of breast cancer. The most successful drugs target three receptors common to most breast cancers (estrogen receptors, progesterone receptors and HER2 receptors). TNBC does not express any of these receptors and, despite many advances in cancer treatment, remains difficult to treat. This project aims to address an unmet clinical need by developing drugs to treat TNBC. With an increasing incidence of cancer and an ageing population, we need to address this problem now to improve future outcomes for the individual and for society. The development of new drugs to treat TNBC will improve quality-of-life for patients and alleviate the economic burden of cancer on society. Tubulin is a protein that is essential for tumour cell replication. Drugs targeting tubulin, e.g. paclitaxel, are used to treat a wide range of cancers and have saved countless lives. Unfortunately drug resistance and side-effects are common, hence development of new drugs is necessary. A large library of anti-tumour β-lactams that interact with tubulin and halt the growth of cancer cells, including TNBC cells, have been developed by our research group. These compounds are amongst the most potent tubulin-targeting agents ever reported. The β-lactams were initially evaluated as a racemic mixture of two isomers known as enantiomers. It is common that one enantiomer of a drug has a better therapeutic profile, although many drugs are still produced as racemates. The next critical step in this project involves chemical synthesis of the enantiomers of our β-lactams. The most biologically active compounds from our series of over 250 analogues have been chosen for synthesis as single enantiomers. Upon completion of synthesis, biological evaluation of their relative potencies in TBNC cells will allow us to determine which has superior activity. The most promising compounds will be progressed for preclinical development to establish a clinical drug candidate with the potential to save lives. The three overall aims of this research project are: 1. Development of efficient methods for chemical synthesis of enantiomerically pure β-lactams. 2. Evaluation of the anti-tumour effects of the β-lactams in breast cancer cells. 3. Development of the best β-lactams as potential clinical drug candidates for treatment of TNBC. The outcomes of the project will be twofold: firstly, advances in the design of novel anti-cancer drugs to treat TNBC and secondly, development of more efficient methods to synthesise enantiomerically pure β-lactams. The methodology developed from the latter can potentially be applied to the synthesis of number of commercially available β-lactam-containing drugs, e.g. ezetimibe.
  Funding Agency

  University of Dublin, Trinity College
  Date From

  September 2018
  Date To

  September 2022
• Title

  From Chemistry to Clinic: Increasing the Solubility and Stability of Promising Drugs for Gastrointestinal Cancers
  Summary

  Successful drugs must overcome many hurdles on their journey to clinical use, and it is essential to have a favourable solubility and stability profile. We aim to improve the solubility and stability of two promising anti-cancer agents, CC12 and pyrazinib, which are under development as adjunct treatments for colorectal cancer and oesophageal adenocarcinoma respectively. Drug development options for the two compounds are limited due to suboptimal physiochemical properties: poor water solubility (CC12 and pyrazinib) and stability (CC12). Extremely poor water solubility limits their options for in vivo testing and delivery to patients. CC12 is unstable and undesired degradation products form in solutions of the drug. This project aims to overcome these limitations by chemical synthesis of stable, water-soluble versions of CC12 and pyrazinib called prodrugs. Prodrugs are compounds with little or no inherent pharmacological activity that are enzymatically converted to the active drug in vivo. Prodrug formation is an excellent option for improving the solubility and stability of drugs. We propose to attach the phosphate ester group to CC12 and pyrazinib to optimise their physiochemical profiles and enable further progression of these promising compounds along the drug delivery pipeline into clinical studies.
  Funding Agency

  University of Dublin, Trinity College
  Date From

  2020
  Date To

  2021
• Title

  Extracellular Vesicles in Allergic Contact Dermatitis (EV-ACD)
  Summary

  Contact allergy is a skin disease that happens when skin comes into contact with harmful chemicals, called contact allergens. Contact allergens cause inflammation and the skin becomes red, itchy and sometimes blistered. These contact allergens can be natural, like metals and those in poison ivy, or synthetic, for example fragrances used in perfumes. We don"t fully understand why some chemicals cause contact allergy whilst others don"t. Skin cells, called keratinocytes, release small vesicles when they are exposed to contact allergens. This project aims to characterise these vesicles and their contents, to understand what is released from keratinocytes. We also aim to determine if the vesicles cause an immune response. The results of this project will help us to learn more about what happens in our skin upon contact with allergens. In the future, this could lead to breakthroughs in the diagnosis and treatment of contact allergy.
  Funding Agency

  Panoz Pharmaceutical Innovation
• Title

  Synthesis and Analysis of Chiral Anti-Tumour Beta-Lactams for Treatment of Aggressive Breast Cancer
  Summary

  Tubulin is a protein that is essential for tumour cell replication. Drugs targeting tubulin, e.g. paclitaxel, are used to treat a wide range of cancers and have saved countless lives. Unfortunately drug resistance and side-effects are common, hence development of new drugs is necessary. A large library of anti-tumour β-lactams that interact with tubulin and halt the growth of cancer cells, including TNBC cells, have been developed by our research group. These compounds are amongst the most potent tubulin-targeting agents ever reported. They target the colchicine-binding site of tubulin, which is distinct from the binding sites targeted by clinically used tubulin-targeting drugs (paclitaxel, vinblastine and vincristine), and hence our compounds could be of value in overcoming multidrug resistance caused by binding-site specific mutations. Our previously synthesised β-lactams were evaluated as racemic mixtures. It is common that one enantiomer of a drug has a better therapeutic profile. Building on our extensive work, the next critical step in this project involves chemical synthesis of the enantiomers of our β-lactams and determination of their enantiomeric excess (optical purity) using chiral HPLC. The most biologically active compounds from our series of over 250 analogues have been chosen for synthesis as single enantiomers. Our objective is to determine if one or both enantiomers are responsible for the antiprolifeative effects. This will allow us to progress this enantiomer along the drug development pipeline as a clinical candidate.
  Funding Agency

  Royal Society of Chemistry
  Date From

  2020
  Date To

  2021
• Title

  eRaDicate: Developing Innovative Ligands for Nuclear Receptors to Eradicate Cancer Relapse
  Summary

  This project aims to develop a strategy for enabling the efficient delivery of selected RAR" antagonist and VDR agonists. This will be achieved through a systematic approach, beginning with the determination of relevant physicochemical properties of the molecules via preformulation studies. Afterwards, the impact of these properties on functional and biopharmaceutical characteristics such as solubility, dissolution, and permeability will be established. Anti-crystal engineering principles based on polymers and/or other excipients will be applied to create supersaturable drug delivery systems, ensuring maximum solubility and flux across the membrane. The mechanism of drug release and the degree of supersaturation will be determined in vitro, with the goal of identifying an optimum delivery system.
  Funding Agency

  Horizon Europe

Pharmacology and pharmaceutical sciences, Biochemistry and cell biology, Other health sciences, Chemical Sciences, Medical, health and life sciences, Immunology, Cancer,

• Outstanding Reviewer Award, European Journal of Medicinal Chemistry 2017
• Trinity College Dublin Postgraduate Research Studentship 2009
• Pharmaceutical Society of Ireland Young Pharmacist's forum: Best poster presentation 2006
• Trinity College Dublin Provost's PhD Project Award 2018
• CAMS-UK Fellowship 2019
• XVIIIth European Conference of GP2A: Best Presentation 2009
• Irish Cancer Society Oncology Scholars Travel Award 2008
• University of Gothenburg Department of Chemistry Postdoctoral Scholarship 2010 - 2012
• Irish Research Council Government of Ireland Postdoctoral Fellowship 2014 - 2016
• Trinity College Dublin Postgraduate Research Studentship (1252) 2006
• Best Poster Presentation, STRATAGEM WG2 Meeting and International Online Symposium on 'Synthesis and nanodelivery strategies for new therapeutic tools against Multidrug Resistant Tumours' (online) 15-Dec-2020
• Trinity College Dublin Foundation Scholarship 2003

• Member of the European Society for Contact Dermatitis Present
• Associate Member of the Institute of Chemistry of Ireland 2024
• Member of the Irish Association for Cancer Research 2023
• Member of the European Association for Cancer Research 2023
• Fellow of Trinity College Dublin Present
• Fellow of the Institute of Chemistry of Ireland Present
• Member of the Pharmaceutical Society of Ireland Present
• Member of the Royal Society of Chemistry Present

• Royal Society of Chemistry Ireland Regional Steering Group - Early Career Representative 2020 - 2023
• Group for the Promotion of Pharmaceutical chemistry in Academia: committee member 2017 - present
• COST Action CA17104 Stratagem - management committee substitute (Ireland) and working group member 2019
• Journal Reviewer (journals including PNAS, RSC Med.Chem., J.Med.Chem., Eur.J.Med.Chem., ACS Med.Chem.Lett.)
• Royal Irish Academy Physical, Chemical & Mathematical Sciences multidisciplinary committee (member) 2022-2026